
David J. Makiya
Supervisory Patent Examiner (ID: 9103, Phone: (571)272-2273 , Office: P/2884 )
| Most Active Art Unit | 2885 |
| Art Unit(s) | 2884, 2875, 2885 |
| Total Applications | 603 |
| Issued Applications | 259 |
| Pending Applications | 28 |
| Abandoned Applications | 317 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17657081
[patent_doc_number] => 20220177546
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => SYSTEMS AND METHODS FOR PRODUCING COLLAGEN 7 COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/598029
[patent_app_country] => US
[patent_app_date] => 2020-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24088
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17598029
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/598029 | SYSTEMS AND METHODS FOR PRODUCING COLLAGEN 7 COMPOSITIONS | Mar 26, 2020 | Pending |
Array
(
[id] => 17611713
[patent_doc_number] => 20220153992
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => BRANCHED AND DEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE
[patent_app_type] => utility
[patent_app_number] => 17/599163
[patent_app_country] => US
[patent_app_date] => 2020-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13803
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17599163
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/599163 | Branched and degradable polyethylene glycol derivative | Mar 25, 2020 | Issued |
Array
(
[id] => 17657048
[patent_doc_number] => 20220177513
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => Process for the Preparation of Abaloparatide
[patent_app_type] => utility
[patent_app_number] => 17/598957
[patent_app_country] => US
[patent_app_date] => 2020-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3409
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17598957
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/598957 | Process for the Preparation of Abaloparatide | Mar 23, 2020 | Pending |
Array
(
[id] => 17611503
[patent_doc_number] => 20220153782
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING A NEUROLOGICAL CONDITION
[patent_app_type] => utility
[patent_app_number] => 17/437628
[patent_app_country] => US
[patent_app_date] => 2020-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11091
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17437628
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/437628 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING A NEUROLOGICAL CONDITION | Mar 23, 2020 | Abandoned |
Array
(
[id] => 16673098
[patent_doc_number] => 20210061861
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-04
[patent_title] => D-PEPTIDIC COMPOUNDS FOR VEGF
[patent_app_type] => utility
[patent_app_number] => 16/826050
[patent_app_country] => US
[patent_app_date] => 2020-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56508
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16826050
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/826050 | D-PEPTIDIC COMPOUNDS FOR VEGF | Mar 19, 2020 | Abandoned |
Array
(
[id] => 18198353
[patent_doc_number] => 20230051872
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => Multivalent D-Peptidic Compounds for Target Proteins
[patent_app_type] => utility
[patent_app_number] => 17/441645
[patent_app_country] => US
[patent_app_date] => 2020-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45507
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17441645
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/441645 | Multivalent D-Peptidic Compounds for Target Proteins | Mar 19, 2020 | Pending |
Array
(
[id] => 16175530
[patent_doc_number] => 20200222498
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-16
[patent_title] => PHARMACEUTICAL CONSTRUCTS WITH ENHANCED BINDING AFFINITY WITH ALBUMIN
[patent_app_type] => utility
[patent_app_number] => 16/823358
[patent_app_country] => US
[patent_app_date] => 2020-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17885
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 209
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16823358
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/823358 | Pharmaceutical constructs with enhanced binding affinity with albumin | Mar 18, 2020 | Issued |
Array
(
[id] => 18389949
[patent_doc_number] => 20230158167
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EMBODIMENT THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/980503
[patent_app_country] => US
[patent_app_date] => 2020-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51919
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16980503
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/980503 | SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EMBODIMENT THEREOF | Mar 8, 2020 | Issued |
Array
(
[id] => 16450869
[patent_doc_number] => 20200360295
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-19
[patent_title] => Enzymatically Cleavable Self-Assembled Nanoparticles for Morphogen Delivery
[patent_app_type] => utility
[patent_app_number] => 16/811023
[patent_app_country] => US
[patent_app_date] => 2020-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9202
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16811023
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/811023 | Enzymatically cleavable self-assembled nanoparticles for morphogen delivery | Mar 5, 2020 | Issued |
Array
(
[id] => 16296290
[patent_doc_number] => 20200282013
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => LOW-DOSE CYTOKINE CO-ADMINISTERED WITH IRGD FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/812107
[patent_app_country] => US
[patent_app_date] => 2020-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5962
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16812107
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/812107 | LOW-DOSE CYTOKINE CO-ADMINISTERED WITH IRGD FOR TREATING CANCER | Mar 5, 2020 | Abandoned |
Array
(
[id] => 19884208
[patent_doc_number] => 12269901
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-08
[patent_title] => Peptide and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/434464
[patent_app_country] => US
[patent_app_date] => 2020-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 6
[patent_no_of_words] => 6086
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17434464
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/434464 | Peptide and use thereof | Mar 4, 2020 | Issued |
Array
(
[id] => 17593566
[patent_doc_number] => 20220143139
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => Modulating Neuroinflammation
[patent_app_type] => utility
[patent_app_number] => 17/435947
[patent_app_country] => US
[patent_app_date] => 2020-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5944
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17435947
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/435947 | Modulating Neuroinflammation | Mar 2, 2020 | Abandoned |
Array
(
[id] => 20593580
[patent_doc_number] => 12577282
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-17
[patent_title] => Galectin-1/ galectin-3 chimeras and multivalent proteins
[patent_app_type] => utility
[patent_app_number] => 17/434616
[patent_app_country] => US
[patent_app_date] => 2020-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 20
[patent_no_of_words] => 22001
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17434616
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/434616 | Galectin-1/ galectin-3 chimeras and multivalent proteins | Feb 27, 2020 | Issued |
Array
(
[id] => 17937080
[patent_doc_number] => 11471512
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-18
[patent_title] => Pharmaceutical compositions of a peptide
[patent_app_type] => utility
[patent_app_number] => 16/801227
[patent_app_country] => US
[patent_app_date] => 2020-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21409
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16801227
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/801227 | Pharmaceutical compositions of a peptide | Feb 25, 2020 | Issued |
Array
(
[id] => 20687696
[patent_doc_number] => 12617831
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-05-05
[patent_title] => Peptide targeting GIP and GLP-2 receptors for treating bone disorders
[patent_app_type] => utility
[patent_app_number] => 17/431598
[patent_app_country] => US
[patent_app_date] => 2020-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 10084
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17431598
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/431598 | Peptide targeting GIP and GLP-2 receptors for treating bone disorders | Feb 20, 2020 | Issued |
Array
(
[id] => 17625633
[patent_doc_number] => 20220160648
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => Composition Comprising Hydrolyzed Collagen and Cannabidiol and Use Thereof
[patent_app_type] => utility
[patent_app_number] => 17/430803
[patent_app_country] => US
[patent_app_date] => 2020-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13642
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17430803
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/430803 | Composition Comprising Hydrolyzed Collagen and Cannabidiol and Use Thereof | Feb 12, 2020 | Abandoned |
Array
(
[id] => 17561737
[patent_doc_number] => 20220125886
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => CO-FORMULATIONS OF AMYLIN ANALOGUES WITH INSULIN ANALOGUES FOR TREATMENT OF DIABETES
[patent_app_type] => utility
[patent_app_number] => 17/430664
[patent_app_country] => US
[patent_app_date] => 2020-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10876
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17430664
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/430664 | CO-FORMULATIONS OF AMYLIN ANALOGUES WITH INSULIN ANALOGUES FOR TREATMENT OF DIABETES | Feb 11, 2020 | Pending |
Array
(
[id] => 20239521
[patent_doc_number] => 12419824
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-23
[patent_title] => Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes
[patent_app_type] => utility
[patent_app_number] => 17/427364
[patent_app_country] => US
[patent_app_date] => 2020-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 7
[patent_no_of_words] => 22660
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17427364
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/427364 | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | Feb 9, 2020 | Issued |
Array
(
[id] => 17593577
[patent_doc_number] => 20220143150
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONIST ANALOG, PROCESS OF PREPARATION AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/428872
[patent_app_country] => US
[patent_app_date] => 2020-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8941
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17428872
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/428872 | GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONIST ANALOG, PROCESS OF PREPARATION AND USES THEREOF | Feb 5, 2020 | Abandoned |
Array
(
[id] => 16621498
[patent_doc_number] => 20210040151
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-11
[patent_title] => MICROMOLECULE POLYPEPTIDE AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/779951
[patent_app_country] => US
[patent_app_date] => 2020-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2442
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16779951
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/779951 | MICROMOLECULE POLYPEPTIDE AND USE THEREOF | Feb 2, 2020 | Abandoned |